Different IgG subclasses possess varying levels of ADCC and CDC activity. Therapeutic antibody drug development requires the selection of a specific IgG subclass backbone, based on a desired ADCC and CDC activity profile. To identify optimal ADCC/CDC profiles for specific targets, it is advantageous to study the effect of chimeric antibodies produced from the same variable region grafted to different subclass Fc domains.
The four IgG subclasses: IgG1, IgG2, IgG3 & IgG4 at 9, 3, 12 and 6 o'clock, respectively.(Photo provided courtesy of University of Birmingham (UK), Department of Rheumatology.)
Upon request, Eureka Therapeutics will produce chimeric
antibodies with different Fc domains using our proprietary
cloning cassettes. We possess cloning cassettes for all IgG
subclasses from both mouse (IgG1, 2a, 2b, and 3) and human
(IgG1, 2, 3 and 4).
Please contact services@eurekainc.com for more
details and service quotes.